Failure of amygdalin to arrest B16 melanoma and BW5147 AKR leukemia.
Parenteral amygdalin was found to be ineffective in C57BL/6 mice with B16 melanoma and in AKR mice with BW5147 lymphatic leukemia, in doses ranging from 50 to 5000 mg/kg.